Plasma insulin-like growth factor I and prostate cancer risk: A prospective study
Plasma insulin-like growth factor I and prostate cancer risk: A prospective study
复制标题
DOI：
10.1126/science.279.5350.563
复制
发表时间：
1998-01-23
期刊：
影响因子：
56.9
通讯作者：
Pollak, M
中科院分区：
文献类型：
--
作者：
Chan, JM;Stampfer, MJ;Pollak, M
胰岛素样生长因子-I（IGF-I）是前列腺上皮细胞的促分裂原。为了研究血浆IGF水平与前列腺癌风险之间的关系，在医生健康研究中对152例病例和152例对照的前瞻性收集的血浆进行了巢式病例对照研究。IGF-I水平与前列腺癌风险之间存在强正相关。IGF-I水平最高四分位数的男性与最低四分位数的男性相比，相对风险为4.3（95%置信区间为1.8至10.6）。这种关联与基线前列腺特异性抗原水平无关。将血浆IGF-I鉴定为前列腺癌风险的预测因子可能对降低风险和治疗有意义。
Insulin-like growth factor-I (IGF-I) is a mitogen for prostate epithelial cells. To investigate associations between plasma IGF levels and prostate cancer risk, a nested case-control study within the Physicians' Health Study was conducted on prospectively collected plasma from 152 cases and 152 controls. A strong positive association was observed between IGF-I levels and prostate cancer risk. Men in the highest quartile of IGF-I levels had a relative risk of 4.3 (95 percent confidence interval 1.8 to 10.6) compared with men in the lowest quartile. This association was independent of baseline prostate-specific antigen levels. Identification of plasma IGF-I as a predictor of prostate cancer risk may have implications for risk reduction and treatment.